FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to pharmaceutical compositions containing a peptide and propylene glycol, to methods of preparing such compositions, and also concerns methods of reducing contamination of injection devices by a peptide composition and reducing sediment formation in the production equipment during manufacturing of the peptide composition. The agonist GLP-1 is used as said peptide in the composition.
EFFECT: reduced contamination of the injection devices during injection.
23 cl, 6 ex, 7 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PEPTIDE ACIDIFYING | 2003 |
|
RU2345062C2 |
METHOD OF CONJUGATING PEPTIDES, MEDIATED BY TRANSGLUTAMINASE | 2005 |
|
RU2385879C2 |
STABLE PREPARATIONS OF INSULIN PEPTIDES | 2005 |
|
RU2413530C2 |
STABILISED PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE | 2004 |
|
RU2421236C2 |
LIPOPHILIC DERIVATIVES OF PEPTIDE HORMONES | 1996 |
|
RU2171261C2 |
STABLE NON-AQUEOUS PHARMACEUTICAL COMPOSITIONS | 2008 |
|
RU2472492C2 |
POLYPEPTIDES SELECTIVE TO GLUCAGON RECEPTORS AND THEIR APPLICATION METHODS | 2017 |
|
RU2760007C2 |
NOVEL GLUCAGON ANALOGUES | 2011 |
|
RU2559320C2 |
NOVEL ANALOGUES OF GLUCAGON-LIKE PEPTIDE, COMPOSITION AND METHOD OF USE | 2010 |
|
RU2557301C2 |
USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
Authors
Dates
2011-06-20—Published
2004-11-18—Filed